Carsten Müller-Tidow focuses on Cancer research, Myeloid leukemia, Leukemia, Myeloid and Molecular biology. His research in Cancer research intersects with topics in Carcinogenesis, Regulation of gene expression, Receptor tyrosine kinase and Fms-Like Tyrosine Kinase 3. The study incorporates disciplines such as Genetics, Haematopoiesis, Wnt signaling pathway, DNA methylation and Transcription factor in addition to Myeloid leukemia.
His Leukemia study combines topics from a wide range of disciplines, such as Myelofibrosis, Philadelphia chromosome and Oncology. His Myeloid study incorporates themes from Cytarabine and Surgery. His research integrates issues of KDM1A, Chromatin immunoprecipitation, RNA interference, Cyclin-dependent kinase complex and Retinoic acid in his study of Molecular biology.
Carsten Müller-Tidow mainly investigates Cancer research, Internal medicine, Myeloid leukemia, Leukemia and Oncology. His Cancer research research includes themes of Haematopoiesis, Stem cell, DNA methylation, Immunology and Receptor tyrosine kinase. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery.
Carsten Müller-Tidow interconnects Fms-Like Tyrosine Kinase 3, Myeloid, Acute promyelocytic leukemia, Transcription factor and Molecular biology in the investigation of issues within Myeloid leukemia. The concepts of his Molecular biology study are interwoven with issues in Gene expression and Gene. His work on Chemotherapy regimen as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science.
The scientist’s investigation covers issues in Internal medicine, Cancer research, Oncology, Myeloid leukemia and Transplantation. As a part of the same scientific study, he usually deals with the Internal medicine, concentrating on Gastroenterology and frequently concerns with Concomitant, Immunosuppression and AL amyloidosis. His Cancer research research includes elements of Haematopoiesis, T cell, Antigen, Single-cell analysis and Bone marrow.
His work carried out in the field of Oncology brings together such families of science as B-cell lymphoma, Adverse effect and Mantle cell lymphoma. His studies deal with areas such as Myeloid, Newly diagnosed, Gene, Leukemia and Fludarabine as well as Myeloid leukemia. His Transplantation research incorporates themes from Cytarabine, Chemotherapy, Clinical endpoint and Cumulative incidence.
His main research concerns Internal medicine, Myeloid leukemia, Cancer research, Oncology and Multiple myeloma. His Internal medicine research focuses on Gastroenterology and how it connects with Concomitant, AL amyloidosis and Transplantation. His Myeloid leukemia research integrates issues from Prognostic variable, Small nucleolar RNA, Cell growth, Myeloid and Leukemia.
Carsten Müller-Tidow has included themes like Progenitor cell, Haematopoiesis and Stem cell in his Myeloid study. His studies in Cancer research integrate themes in fields like Ex vivo, Amanitin, Tumour heterogeneity, Gene expression profiling and Single-cell analysis. The Oncology study combines topics in areas such as Newly diagnosed and Adverse effect.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.
Ping Ji;Sven Diederichs;Wenbing Wang;Sebastian Böing.
The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.
Lars Henning Schmidt;Tilmann Spieker;Steffen Koschmieder;Julia Humberg.
Journal of Thoracic Oncology (2011)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk;Weihsu Claire Chen;Stefanie Göllner;Louise Howell.
Nature Medicine (2012)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton;G. Vignir Helgason;Mirle Schemionek;Bin Zhang.
Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
Thomas Büchner;Wolfgang E. Berdel;Claudia Haferlach;Torsten Haferlach.
Journal of Clinical Oncology (2009)
Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells
Carsten Müller-Tidow;Björn Steffen;Thomas Cauvet;Lara Tickenbrock.
Molecular and Cellular Biology (2004)
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
Masao Mizuki;Joachim Schwäble;Joachim Schwäble;Joachim Schwäble;Claudia Steur;Claudia Steur;Claudia Steur;Chunaram Choudhary;Chunaram Choudhary;Chunaram Choudhary.
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
Chunaram Choudhary;Jesper V. Olsen;Jesper V. Olsen;Christian Brandts;Jürgen Cox.
Molecular Cell (2009)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Röllig;Hubert Serve;Andreas Hüttmann;Richard Noppeney.
Lancet Oncology (2015)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve;Utz Krug;Ruth Wagner;M. Cristina Sauerland.
Journal of Clinical Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: